Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/darunavir - Janssen R&D Ireland

Drug Profile

Cobicistat/darunavir - Janssen R&D Ireland

Alternative Names: Darunavir/cobicistat; DRV/COBI; G 006; JNJ-48763364/TMC114; Prezcobix; Rezolsta; TMC114/ JNJ-48763364

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Carbamates; Deoxyribonucleosides; Morpholines; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Sep 2021 Biomarkers information updated
  • 01 Apr 2021 Janssen Research & Development completes a phase I trial (In volunteers) in Belgium (NCT04208061)
  • 28 Mar 2021 No recent reports of development identified for phase-I development in HIV-1-infections(In adolescents, In children) in USA (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top